Company’s Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve targeted in vivo conjugation of 177 Lu-DOTA Increased tumor retention and total tumor uptake anticipated by using optimized universal Radiohapten Company plans to initiate a Trial 1001 Bridge study (Part 2A) with... Read More